Effects of long-term therapy with labetalol on lipoprotein metabolism in patients with mild hypertension.
The effects of labetalol on serum lipoproteins, the intravenous fat tolerance test (IVFTT) and lipoprotein lipase (LPL) and hepatic lipase (HL) activities were studied in 16 patients with mild hypertension before and after 6 months of therapy. Most patients were found to be normotensive on 200 mg labetalol/day. Before therapy the mean concentration of serum TG was 0.75 +/- 0.21 (SD) mmol/l, of total cholesterol 5.41 +/- 1.25 mmol/l and of HDL cholesterol 1.67 +/- 0.61 mmol/l. After labetalol no significant changes were found in the concentrations of TG and cholesterol in the VLDL, LDL and HDL fractions. The mean values for the IVFTT and for LPL and HL activities were in the normal range and remained unchanged during therapy.
D000328:Adult; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D007741:Labetalol / Q000627:therapeutic use*; D008049:Lipase / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D005217:Fat Emulsions, Intravenous; D008074:Lipoproteins; D006493:Heparin; D008049:Lipase; D007741:Labetalol